Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025)
Inhibrx Biosciences (INBX) reported Receivables - Other of $177000.0 for Q4 2025, down 10.15% year-over-year from $197000.0 in Q4 2024, and down 75.65% quarter-over-quarter from $727000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Receivables - Other data on file, last reported at $177000.0 in Q4 2025.
- Receivables - Other for Q4 2025 came in at $177000.0, down 10.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $177000.0 (down 10.15% YoY), and the FY2025 annual result was $177000.0, down 10.15% from the prior year.
- Receivables - Other retreated to $177000.0 in Q4 2025 per INBX's latest filing, from $727000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $952000.0 in Q2 2024 and troughed at $177000.0 in Q4 2025.
- A 3-year average of $565000.0 and a median of $667000.0 in 2023 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other slumped 67.55% in 2024, then dropped 10.15% in 2025.
- A 3-year view of Receivables - Other shows it stood at $607000.0 in 2023, then tumbled by 67.55% to $197000.0 in 2024, then declined by 10.15% to $177000.0 in 2025.
- Business Quant data shows INBX's Receivables - Other at $177000.0 in Q4 2025, $727000.0 in Q3 2025, and $730000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 177,000.00 |
| Dec 31, 2025 | 177,000.00 |
| Sep 30, 2025 | 727,000.00 |
| Sep 30, 2025 | 727,000.00 |
| Jun 30, 2025 | 730,000.00 |
| Jun 30, 2025 | 730,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Jun 30, 2024 | 952,000.00 |
| Jun 30, 2024 | 952,000.00 |
| Dec 31, 2023 | 607,000.00 |
| Dec 31, 2023 | 607,000.00 |